Clinical Usefulness of Cortisol, Antinuclear Antibodies and High-sensitivity C-reactive Protein in Acute Pancreatitis
1 other identifier
observational
50
0 countries
N/A
Brief Summary
Acute pancreatitis (AP) is a potentially life-threatening disease with varying severity of presentation. Nearly 60%-80% of all cases of AP in developed countries are attributable to either gallstone disease or alcohol abuse. The incidence is similar in both sexes, although alcohol abuse is the more common cause in men and gallstones is the more common cause in women.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Feb 2019
Shorter than P25 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 2, 2019
CompletedFirst Posted
Study publicly available on registry
February 5, 2019
CompletedStudy Start
First participant enrolled
February 25, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 20, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
May 30, 2019
CompletedFebruary 5, 2019
February 1, 2019
3 months
February 2, 2019
February 2, 2019
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
The mean difference of cortisol before and after treatment
Cortisol mean difference will be measured by immunofluorescence in acute pancreatitis.
72 hours
Study Arms (2)
Group I:
Fifty AP patients on admission
Group II:
The previous AP patients after 72 hours
Interventions
Cortisol will be measured by immunofluorescence and correlated with ANA and hs-CRP
Eligibility Criteria
Acute pancreatitis
You may qualify if:
- abdominal pain consistent with AP
- serum amylase activity at least 3 times greater than the upper limit of normal
- Patients of age 18 years or more who are willing to participate in the study and give their consent for same.
You may not qualify if:
- Patients with severe liver disease, pulmonary embolus, sepsis, and renal failure were excluded from the study.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Publications (4)
Zhang XP, Zhang L, Wang Y, Cheng QH, Wang JM, Cai W, Shen HP, Cai J. Study of the protective effects of dexamethasone on multiple organ injury in rats with severe acute pancreatitis. JOP. 2007 Jul 9;8(4):400-12.
PMID: 17625291BACKGROUNDImamura T, Tanaka S, Yoshida H, Kitamura K, Ikegami A, Takahashi A, Niikawa J, Mitamura K. Significance of measurement of high-sensitivity C-reactive protein in acute pancreatitis. J Gastroenterol. 2002;37(11):935-8. doi: 10.1007/s005350200157.
PMID: 12483249BACKGROUNDNebiker CA, Staubli S, Schafer J, Bingisser R, Christ-Crain M, Dell-Kuster S, Mueller C, Scamardi K, Viehl CT, Kolleth D, von Holzen U, Oertli D, Rosenthal R. Cortisol Outperforms Novel Cardiovascular, Inflammatory, and Neurohumoral Biomarkers in the Prediction of Outcome in Acute Pancreatitis. Pancreas. 2018 Jan;47(1):55-64. doi: 10.1097/MPA.0000000000000962.
PMID: 29215538BACKGROUNDSmyk DS, Rigopoulou EI, Koutsoumpas AL, Kriese S, Burroughs AK, Bogdanos DP. Autoantibodies in autoimmune pancreatitis. Int J Rheumatol. 2012;2012:940831. doi: 10.1155/2012/940831. Epub 2012 Jul 12.
PMID: 22844291BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
February 2, 2019
First Posted
February 5, 2019
Study Start
February 25, 2019
Primary Completion
May 20, 2019
Study Completion
May 30, 2019
Last Updated
February 5, 2019
Record last verified: 2019-02